Press Releases2021-02-08T17:21:57-05:00

News & Insights

Impact, observations, and insights to advance translational intelligence

All
Trends & Insights
COVID-19 Data Initiative
Press Releases
Conferences & Events

Precision Medicine Group Secures Major Investment from Blackstone

Press Releases|

New York, NY & Bethesda, MD — November 20, 2020 — Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, Ethan Leder and Mark Clein, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT, and Vida Ventures.

(more…)

QuartzBio™, part of Precision for Medicine, Expands Computational Biology and Launches Boston Office

Press Releases|

July 16, 2019 — Boston, MA — QuartzBio™, part of Precision for Medicine, today announced a significant expansion of its computational biology and multiomic data integration capabilities through the launch of a Boston-based office. The new office is one of many recent investments in Artificial Intelligence and computational biology expertise to cement its position as a leading solution for the integration, and analysis of biological data to support biomarker-guided drug development.

(more…)

Precision for Medicine Acquires Industry-leading Artificial Intelligence Technology

Press Releases|

March 6, 2019 — Bethesda, MD — Precision for Medicine, part of Precision Medicine Group, today announced the acquisition of SimplicityBio, adding artificial intelligence to Precision’s QuartzBio™ multiomic data integration and informatics platform. The addition of an artificial intelligence engine to QuartzBio provides Precision’s clients the most robust, sophisticated end-to-end solution for the “big data” challenge observed in biomarker-guided drug development—furthering their mission of maximizing the value and utility of biomarker data generated in the course of a clinical trial.

(more…)